Poortmans G
Department of Anesthesiology, University Hospitals, Catholic University Louvain, UZ Gasthuisberg, Herestraat 49, 3000 Leuven.
Acta Anaesthesiol Belg. 2001;52(4):403-7.
In recent years, a lot of concern about the use of oral antidiabetics has been raised. Several studies indicate an excess cardiovascular morbidity and mortality associated with the use of oral antidiabetics in the treatment of non-insulin dependent diabetes mellitus. Only recently, the identification of the KATP-channels and it's pivotal role in the phenomenon of ischemic preconditioning has lead to a clear explanation of these disturbing findings. The antagonism of KATP-channels by the sulphonylurea-class type of oral antidiabetics interferes with ischemic preconditioning. The question has been raised what to do with oral antidiabetics during the perioperative setting with it's additional burden imposed on the cardiovascular system. In this article the historical background, the phenomenon of ischemic preconditioning, the importance of KATP-channels and the working mechanism of the oral antidiabetics are highlighted. A few thoughts on the use of oral antidiabetics in the perioperative setting are developed and clinical conclusions drawn.
近年来,人们对口服抗糖尿病药物的使用引发了诸多关注。多项研究表明,在治疗非胰岛素依赖型糖尿病时,使用口服抗糖尿病药物会导致心血管疾病发病率和死亡率增加。直到最近,KATP通道的发现及其在缺血预处理现象中的关键作用,才对这些令人不安的研究结果给出了明确解释。磺脲类口服抗糖尿病药物对KATP通道的拮抗作用会干扰缺血预处理。在围手术期,由于心血管系统会承受额外负担,因此出现了关于如何使用口服抗糖尿病药物的问题。本文重点介绍了其历史背景、缺血预处理现象、KATP通道的重要性以及口服抗糖尿病药物的作用机制。文中还就围手术期口服抗糖尿病药物的使用提出了一些想法,并得出了临床结论。